Cargando…
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
SIMPLE SUMMARY: Data about the efficacy of trastuzumab emtansine (T-DM1) following pertuzumab treatment is limited due to the simultaneous development of the two drugs. Thus, the aim of this study was to investigate the efficacy of T-DM1 after previous treatment with pertuzumab in a large, real-worl...
Autores principales: | Michel, Laura L., Hartkopf, Andreas D., Fasching, Peter A., Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Häberle, Lothar, Ettl, Johannes, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Volz, Bernhard, Huebner, Hanna, Wimberger, Pauline, Hielscher, Carsten, Mundhenke, Christoph, Kurbacher, Christian, Wuerstlein, Rachel, Untch, Michael, Overkamp, Friedrich, Huober, Jens, Janni, Wolfgang, Taran, Florin-Andrei, Lux, Michael P., Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, Fehm, Tanja N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603111/ https://www.ncbi.nlm.nih.gov/pubmed/33080911 http://dx.doi.org/10.3390/cancers12103021 |
Ejemplares similares
-
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020) -
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020) -
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018) -
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
por: Schneeweiss, Andreas, et al.
Publicado: (2020) -
Return of individual genomic research results within the PRAEGNANT multicenter registry study
por: Huebner, Hanna, et al.
Publicado: (2022)